Connor, Clark & Lunn Investment Management (CC&L)
BNGO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Bionano Genomics BNGO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-880
Closed -$2.9M – 1086
2021
Q3 		$2.9M Buy
+880
New +$3.08M 0.02% 450

Other funds holding BNGO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BNGO Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Bionano Genomics (BNGO) in Q4 2021, closing a stake of 880 shares — an estimated $2.9M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BNGO in Q3 2021 and held it in 1 quarter. The position peaked at $2.9M in Q3 2021. 149 funds tracked by Wall St. Rank hold BNGO as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Bionano Genomics position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 880 Bionano Genomics shares in Q4 2021, an estimated $2.9M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Bionano Genomics in Q3 2021 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Bionano Genomics position peaked at $2.9M in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.